KDR and primitive neuroectodermal tumor: Bevacizumab which targets VEGF and three tyrosine kinase inhibitors: pazopanib, sorafenib, and sunitinib—all with activity against VEGF receptor (VEGFR)—have been evaluated in prospective trials of patients with advanced PNET.